[go: up one dir, main page]

BRPI0415773A - derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer - Google Patents

derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer

Info

Publication number
BRPI0415773A
BRPI0415773A BRPI0415773-7A BRPI0415773A BRPI0415773A BR PI0415773 A BRPI0415773 A BR PI0415773A BR PI0415773 A BRPI0415773 A BR PI0415773A BR PI0415773 A BRPI0415773 A BR PI0415773A
Authority
BR
Brazil
Prior art keywords
treatment
disease states
cancer
application
indolinone derivatives
Prior art date
Application number
BRPI0415773-7A
Other languages
English (en)
Inventor
Damian Arnaiz
Judi Bryant
Yuo-Ling Chou
Richard I Feldman
Paul Hrvatin
Imadul Islam
Monica Kochanny
Wheeseong Lee
Mark Polokoff
Hongyi Yu
Shendong Yuan
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0415773A publication Critical patent/BRPI0415773A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS DE INDOLINONA E SUA APLICAçãO NO TRATAMENTO DE ESTADOS DE DOENçA TAIS COMO CáNCER". Derivados de indolinona, tais como compostos da fórmula (I): em que A, m, n, R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 5¬ e R¬ 6¬ são descritos neste relatório, são revelados neste relatório como sendo úteis no tratamento de mamíferos tendo estados de doença aliviados pela inibição da atividade de PDK-1.
BRPI0415773-7A 2003-10-24 2004-10-22 derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer BRPI0415773A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51408103P 2003-10-24 2003-10-24
PCT/US2004/035262 WO2005040116A2 (en) 2003-10-24 2004-10-22 Indolinone derivatives and their use in treating disease-states such as cancer

Publications (1)

Publication Number Publication Date
BRPI0415773A true BRPI0415773A (pt) 2006-12-26

Family

ID=34520168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415773-7A BRPI0415773A (pt) 2003-10-24 2004-10-22 derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer

Country Status (14)

Country Link
US (1) US7105563B2 (pt)
EP (1) EP1680401A2 (pt)
JP (1) JP2007509173A (pt)
KR (1) KR20060123184A (pt)
CN (1) CN1898205A (pt)
AU (1) AU2004284084A1 (pt)
BR (1) BRPI0415773A (pt)
CA (1) CA2541460A1 (pt)
IL (1) IL174788A0 (pt)
MX (1) MXPA06004438A (pt)
NO (1) NO20062357L (pt)
RU (1) RU2006117635A (pt)
WO (1) WO2005040116A2 (pt)
ZA (1) ZA200604149B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
JP2007512353A (ja) * 2003-11-26 2007-05-17 ザ スクリプス リサーチ インスティテュート 高機能インドリノン系プロテインキナーゼ阻害剤
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
CA2646638A1 (en) * 2006-04-24 2007-11-01 Boehringer Ingelheim International Gmbh 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
ES2565683T3 (es) * 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
WO2009033033A2 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
EP2283006B1 (en) 2008-04-24 2015-02-25 F2G Limited Pyrrole antifungal agents
CA2729745A1 (en) * 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
WO2010001167A2 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Novel process
CN101397295B (zh) * 2008-11-12 2012-04-25 深圳微芯生物科技有限责任公司 作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
EP2246326A1 (de) 2009-05-02 2010-11-03 Bayer CropScience AG Verfahren zur Herstellung von Oxindolen und ortho-substituierten Anilinen und ihre Verwendung als Zwischenprodukte für Synthesen
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
CN102283826A (zh) * 2010-06-21 2011-12-21 中国医学科学院基础医学研究所 维甲酸及其类似物用于治疗tsc1/tsc2失活或其上游通路活化导致的肿瘤
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
WO2012028162A1 (de) 2010-09-01 2012-03-08 Bayer Cropscience Ag Verfahren zur herstellung von oxindolen und ortho-substituierten anilinen und ihre verwendung als zwischenprodukte für synthesen
WO2012058780A1 (en) 2010-11-01 2012-05-10 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
CN102688234B (zh) * 2011-03-21 2015-07-29 华东理工大学 吲哚酮衍生物作为rsk2抑制剂的合成与应用
US8969361B2 (en) 2012-04-20 2015-03-03 Annji Pharmaceutical Co., Ltd. Cyclopropanecarboxylate esters of purine analogues
JP6378308B2 (ja) * 2013-03-13 2018-08-22 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
CN104211632B (zh) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 具有酪氨酸激酶抑制活性的2‑吲哚酮衍生物及其制备方法与应用
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
WO2016055454A1 (en) * 2014-10-06 2016-04-14 International Society For Drug Development S.R.L. Pharmaceutical combination for the treatment of tumors
SI3221308T1 (sl) 2014-11-21 2018-12-31 F2G Limited Antimikotiki
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
EP2020408B1 (en) 1998-05-29 2013-06-26 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitor
EP1149105B1 (en) 1998-12-17 2008-02-27 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
DK1149106T3 (da) 1998-12-17 2003-07-14 Hoffmann La Roche 4,5-azolo-oxindoler
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
DE69912479T2 (de) 1998-12-17 2004-07-22 F. Hoffmann-La Roche Ag 4- und 5-alkynyloxindole sowie 4- und 5-alkenyloxindole
JP2002540096A (ja) 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
JP2003535038A (ja) 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
CA2407799A1 (en) 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
EP1434774A1 (en) 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
AU2002360753B2 (en) * 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
DE60329831D1 (de) * 2003-06-10 2009-12-10 Biondi Ricardo Miguel Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung

Also Published As

Publication number Publication date
ZA200604149B (en) 2007-11-28
RU2006117635A (ru) 2007-12-10
EP1680401A2 (en) 2006-07-19
US7105563B2 (en) 2006-09-12
NO20062357L (no) 2006-07-14
WO2005040116A2 (en) 2005-05-06
CN1898205A (zh) 2007-01-17
JP2007509173A (ja) 2007-04-12
KR20060123184A (ko) 2006-12-01
MXPA06004438A (es) 2006-06-20
US20050090541A1 (en) 2005-04-28
WO2005040116A3 (en) 2005-06-16
IL174788A0 (en) 2006-08-20
CA2541460A1 (en) 2005-05-06
AU2004284084A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
BRPI0415773A (pt) derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer
BR0109188A (pt) Diarilaminas 5-amida substituìdas como inibidores de mex
BR0115605A (pt) Derivados de naftaleno
EA200802213A1 (ru) Способы лечения заболеваний крови
BR0208338A (pt) Derivados de piridina
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
BRPI0414598A (pt) indóis substituìdos
BR0111981A (pt) herbicidas de piridina substituìda
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
EA200401398A1 (ru) Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
BR0316496A (pt) Quinolin-, isoquinolin-, e quinazolin-oxialquilamidas e seu emprego como fungicidas
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
BRPI0410995A (pt) derivados de n-alquinil-2-(arilóxi substituìdo)alquiltioamida como fungicidas
BRPI0412411A (pt) tetrahidro-1h-pirazol[3,4-c]piridinas substituìdas, composições que as contêm e utilização
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
ATE484508T1 (de) Furylverbindungen
MX2007006397A (es) Derivados de tetrahidropirano.
CY1108808T1 (el) Ενωσεις μοτιλιδης
UY25712A1 (es) Benzamidas sustituidas y su aplicación en medicamentos
ATE452896T1 (de) C3-cyanoepothilonderivate
ATE289810T1 (de) Ecteinascidinderivate
ES2169886T3 (es) Derivados condensados de la piperidina como inhibidor de sintesis de monoxido de nitrogeno.
BRPI0412744A (pt) derivados de combretastatina com ação citotóxica
BRPI0408389A (pt) derivados de cromeno como agentes antiinflamatórios

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]